| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
INSERM U 58, 60 rue de Navacelles, 34090 Montpellier [E. D., P. B., F. T., J-C. N., M. P., D. G.], and Laboratoire de Biochimie II, Faculté de Pharmacie, avenue Charles Flahaut, Montpellier Cédex 01 [D. G.], France
Most breast tumors show estrogen-dependent growth and are thus susceptible to antiestrogenic therapy. MCF-7 cells, obtained from a human estrogen-dependent breast carcinoma, are widely used for studying the modulation of estrogenic responses by different effectors. All-trans-retinoic acid (RA) and 1,25-dihydroxyvitamin D3 (Vit D3) inhibited estrogen-induced growth of MCF-7 cells and their effect was potentiated by the classical antiestrogen, hydroxytamoxifen. In MCF-7 cells, we found that RA and Vit D3 also inhibited estrogen-induced transcription; this was shown both for an endogenous gene (pS2) and for various exogenous transfected genes. Their inhibitory effect could not be reversed by increasing estradiol concentrations, showing that contrary to classical antiestrogens, they did not compete with estradiol to bind the estrogen receptor (ER).
Analysis of the inhibitory mechanisms indicates that RA and Vit D3 receptors can directly or indirectly impair the binding of ER to the estrogen responsive element. The antagonist effect of RA would be found especially at DNA level since it seems to essentially involve an estrogen responsive element. The antagonist effect of Vit D3 would be found especially at the ER level since it seems to concern estrogen binding and dimerization domains of ER.
We conclude that the antiestrogenic effects of RA and Vit D3 are similar since they can, via their receptors, interfere with estrogenic action at the estrogen responsive element level but that they are not identical since different molecular mechanisms are involved.
1 To whom requests for reprints should be addressed.
Received 9/16/93. Accepted 1/14/94.
This article has been cited by other articles:
|
|
 |
|
  J. Laganiere, G. Deblois, and V. Giguere Functional Genomics Identifies a Mechanism for Estrogen Activation of the Retinoic Acid Receptor {alpha}1 Gene in Breast Cancer Cells Mol. Endocrinol., June 1, 2005; 19(6): 1584 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. White, M. M. Yore, D. Deng, and M. J. Spinella Limiting Effects of RIP140 in Estrogen Signaling: POTENTIAL MEDIATION OF ANTI-ESTROGENIC EFFECTS OF RETINOIC ACID J. Biol. Chem., March 4, 2005; 280(9): 7829 - 7835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Bernardi, D. L. Trump, W.-D. Yu, T. F. McGuire, P. A. Hershberger, and C. S. Johnson Combination of 1{alpha},25-Dihydroxyvitamin D3 with Dexamethasone Enhances Cell Cycle Arrest and Apoptosis: Role of Nuclear Receptor Cross-Talk and Erk/Akt Signaling Clin. Cancer Res., December 1, 2001; 7(12): 4164 - 4173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Decensi, H. Johansson, R. Miceli, L. Mariani, T. Camerini, E. Cavadini, M. G. Di Mauro, A. Barreca, A. G. Gonzaga, S. Diani, et al. Long-Term Effects of Fenretinide, a Retinoic Acid Derivative, on the Insulin-like Growth Factor System in Women with Early Breast Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2001; 10(10): 1047 - 1053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Swami, A. V. Krishnan, and D. Feldman 1{{alpha}},25-Dihydroxyvitamin D3 Down-Regulates Estrogen Receptor Abundance and Suppresses Estrogen Actions in MCF-7 Human Breast Cancer Cells Clin. Cancer Res., August 1, 2000; 6(8): 3371 - 3379. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. GARCÍA RATO, J. GARCÍA PEDRERO, M. A. MARTÍNEZ, B. DEL RIO, P. S. LAZO, and S. RAMOS Melatonin blocks the activation of estrogen receptor for DNA binding FASEB J, May 1, 1999; 13(8): 857 - 868. [Abstract] [Full Text]
|
|
|
|
 |
|
 A.-C. Lundin, P. Soderkvist, B. Eriksson, M. Bergman-Jungestrom, and S. Wingren Association of Breast Cancer Progression with a Vitamin D Receptor Gene Polymorphism Cancer Res., May 1, 1999; 59(10): 2332 - 2334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sun, W. Porter, and S. Safe Estrogen-Induced Retinoic Acid Receptor {alpha}1 Gene Expression: Role of Estrogen Receptor-Sp1 Complex Mol. Endocrinol., June 1, 1998; 12(6): 882 - 890. [Abstract] [Full Text]
|
|
|
|
|
|
C. Teixeira and M. A. C. Pratt CDK2 Is a Target for Retinoic Acid-Mediated Growth Inhibition in MCF-7 Human Breast Cancer Cells Mol. Endocrinol., August 1, 1997; 11(9): 1191 - 1202. [Abstract] [Full Text]
|
|
|
|
|
|
A. Joyeux, V. Cavaillès, P. Balaguer, and J. C. Nicolas RIP 140 Enhances Nuclear Receptor-Dependent Transcription in Vivo in Yeast Mol. Endocrinol., February 1, 1997; 11(2): 193 - 202. [Abstract] [Full Text]
|
|
|
|
|
|
M. A.C. Pratt, D. Deonarine, C. Teixeira, D. Novosad, B. F. Tate, and J. F. Grippo The AF-2 Region of the Retinoic Acid Receptor alpha Mediates Retinoic Acid Inhibition of Estrogen Receptor Function in Breast Cancer Cells J. Biol. Chem., August 23, 1996; 271(34): 20346 - 20352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kogai, J. J. Schultz, L. S. Johnson, M. Huang, and G. A. Brent Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line PNAS, July 18, 2000; 97(15): 8519 - 8524. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
